CoChat

An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)

Open access
Lee, Shin-Wha, Kim, Yong-Man, Cho, Chi Heum, Kim, Young Tae, Kim, Seok Mo, Hur, Soo Young, Kim, Jae-Hoon, Kim, Byoung-Gie, Kim, Seung-Cheol, Ryu, Hee-Sug, Kang, Soon Beom · 2018 · Cancer Research and Treatment
Cited by 94

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel.Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and MethodsIn this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m 2 or Genexol 175 mg/m 2 with 5 area under the curve carboplatin every 3 weeks (6 cycles).The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). ResultsOf 131 enrolled patients, 98 were included in intention-to-treat analysis.Mean dosages were 260.00±0.00mg/m 2 Genexol-PM or 174.24±3.81mg/m 2 Genexol.Median followup was 18.0 months (range, 6.1 to 33.8 months).ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%).Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550).Overall, six patients died.Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%,p=0.120).Peripheral neuropathy incidences were 84.0%versus 64.6% (p= 0.148).Peripheral neuropathy of !grade 3 occurred in one patient receiving Genexol.All toxicities were manageable.Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen.Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4143/crt.2016.376

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Lee, S.-W., Kim, Y.-M., Cho, C. H., Kim, Y. T., Kim, S. M., Hur, S. Y., Kim, J.-H., Kim, B.-G., Kim, S.-C., Ryu, H.-S., & Kang, S. B.
Venue
Cancer Research and Treatment
Published
2018-01-15
Volume
50
Issue
1
Pages
195-203
ISSN
  • 1598-2998 (ISSN-L)
  • 2005-9256
OpenAlex
W2597887107
Cited by
94
References
6
FWCI
4.87
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.